<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24891">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694914</url>
  </required_header>
  <id_info>
    <org_study_id>0908018</org_study_id>
    <secondary_id>2010-A00234-35</secondary_id>
    <nct_id>NCT01694914</nct_id>
  </id_info>
  <brief_title>Comparative Study of Two Corneal Graft Storage Media: New Animal Compound Free Medium Versus Reference Medium</brief_title>
  <official_title>Comparative Study of Two Corneal Graft Storage Media: New Animal Compound Free Medium Versus Reference Medium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, all commercially available corneal organ culture media contain foetal calf serum
      (FCS) and sometimes other compounds extracted from animals. These compounds are necessary
      for corneal cell survival but are problematic because they theoretically have risk of
      anthropozoonosis transmission, especially for new variant of CJD and the variability between
      FCS batches influence graft quality. Our laboratory research allowed in vitro and ex vivo
      validation of a new medium free compound animal. We proved its superiority over conventional
      medium containing 2% FCS for endothelial cell survival during the storage time. The goal of
      this clinical trial is now to assess its superiority in patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the primary outcome is the endothelial cell density (ECD) of the corneal grafts.</measure>
    <time_frame>one year after graft</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Corneal Transplantation</condition>
  <arm_group>
    <arm_group_label>Animal Compound Free Medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm receive a corneal graft stored in organ culture in a animal compound free medium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>organ culture medium containing 2% of fœtal calf serum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm receive a corneal graft stored in organ culture in a commercial organ culture medium containing 2% of fœtal calf serum</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>corneal graft</intervention_name>
    <arm_group_label>Animal Compound Free Medium</arm_group_label>
    <arm_group_label>organ culture medium containing 2% of fœtal calf serum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients

          -  over 18 years of age

          -  Clinically proven corneal disease

          -  Registered on the French National waiting list (GLAC)

          -  Patient informed consent

          -  Patient who needs a 8.25mm of diameter perforating keratoplasty, either isolated or
             combined with lens surgery

          -  Low immune rejection risk (&lt; 2 quadrants of neovascularization, no previous history
             of herpetic keratitis nor graft rejection)

          -  No previous history of glaucoma or elevated intra ocular pressure (&gt;22 mm

        Exclusion Criteria:

          -  Patient is unlikely to comply with the requirements of the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Thuret, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles Thuret, MD-PhD</last_name>
    <phone>(0)477120570</phone>
    <phone_ext>+33</phone_ext>
    <email>gilles.thuret@univ-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine Labruyere, CRA</last_name>
    <phone>(0)477120469</phone>
    <phone_ext>+33</phone_ext>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bernard Delbosc, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frédéric Chiambaretta, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Paul Romanet, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles Thuret, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>September 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corneal Transplantation</keyword>
  <keyword>corneal organ culture medium</keyword>
  <keyword>free animal compound medium</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
